Ascentage Pharma Group International (AAPG)vsAbbVie Inc (ABBV)
AAPG
Ascentage Pharma Group International
$21.66
+0.74%
HEALTHCARE · Cap: $2.01B
ABBV
AbbVie Inc
$202.78
+0.61%
HEALTHCARE · Cap: $358.55B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 10842% more annual revenue ($62.82B vs $574.12M). ABBV leads profitability with a 5.8% profit margin vs -216.5%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
AAPG
Avoid29
out of 100
Grade: F
ABBV
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+6.8%
Fair Value
$26.39
Current Price
$21.66
$4.73 discount
Margin of Safety
-19.7%
Fair Value
$168.33
Current Price
$202.78
$34.45 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 117.0% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 31.6%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Areas to Watch
Trading at 10.4x book value
0.0% earnings growth
Weak financial health signals
ROE of -154.6% — below average capital efficiency
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 45.8%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AAPG
The strongest argument for AAPG centers on Revenue Growth. Revenue growth of 117.0% demonstrates continued momentum.
Bull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.
Bear Case : AAPG
The primary concerns for AAPG are Price/Book, EPS Growth, Piotroski F-Score.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 98.9x leaves little room for execution misses.
Key Dynamics to Monitor
AAPG profiles as a hypergrowth stock while ABBV is a value play — different risk/reward profiles.
AAPG carries more volatility with a beta of 0.72 — expect wider price swings.
AAPG is growing revenue faster at 117.0% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 29/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ascentage Pharma Group International
HEALTHCARE · BIOTECHNOLOGY · USA
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company is headquartered in Suzhou, China.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?